These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6169362)

  • 81. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug.
    Schallreuter KU; Pittelkow MR
    Arch Dermatol; 1987 Nov; 123(11):1494-8. PubMed ID: 2445297
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anthralin: how does it act and are there more favourable derivatives?
    Mahrle G; Bonnekoh B; Wevers A; Hegemann L
    Acta Derm Venereol Suppl (Stockh); 1994; 186():83-4. PubMed ID: 8073848
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [PUVA and anthraline therapy of psoriasis, a clinical, histological and autoradiographic comparison].
    Pullmann H; Zingheim M; Steigleder GK; Orfanos CE
    Z Hautkr; 1976 Oct; 51(20):861-71. PubMed ID: 983210
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The treatment of chronic psoriasis a two-centre comparative study.
    Khan SA; Williamson DM; Gatecliff M; Tosh J
    Practitioner; 1981 Jun; 225(1356):932-4. PubMed ID: 7029508
    [No Abstract]   [Full Text] [Related]  

  • 85. Clobetasol propionate ointment compared with dithranol in Lassar's paste in the treatment of psoriasis.
    Marriott PJ; Munro DD
    Br J Dermatol; 1976 Mar; 94 suppl 12():101-6. PubMed ID: 1268069
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Psoriasis therapy with retinoid].
    Marghescu S; Lubach D; Rudolph PO
    Z Hautkr; 1982 Oct; 57(19):1410-20. PubMed ID: 6755934
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Suppression of cignolin-induced erythema by tar].
    Schulze HJ
    Z Hautkr; 1984 May; 59(10):659-62. PubMed ID: 6741205
    [No Abstract]   [Full Text] [Related]  

  • 88. Pharmaceutical formulations of anthralin.
    Whitefield M
    Br J Dermatol; 1981 Aug; 105 Suppl 20():28-32. PubMed ID: 7284260
    [No Abstract]   [Full Text] [Related]  

  • 89. Anthralin and tar with UVB increase epidermal cell proliferation in asebia mice.
    Brown WR; Rogozinski TT; Ramsay CA
    Clin Exp Dermatol; 1988 Jul; 13(4):248-51. PubMed ID: 3246091
    [No Abstract]   [Full Text] [Related]  

  • 90. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes.
    Reichert U; Jacques Y; Grangeret M; Schmidt R
    J Invest Dermatol; 1985 Feb; 84(2):130-4. PubMed ID: 2578530
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Unusual mitochondrial reaction in psoriatic keratinocytes.
    Klug H; Schulze P
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1988; 56(3):201-3. PubMed ID: 2906191
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Psoriasis: a dynamic disease.
    Mali JW
    Br J Dermatol; 1979 Dec; 101(6):725-30. PubMed ID: 93968
    [No Abstract]   [Full Text] [Related]  

  • 93. Keratin 17: a useful marker in anti-psoriatic therapies.
    de Jong EM; van Vlijmen IM; van Erp PE; Ramaekers FC; Troyanovski SM; van de Kerkhof PC
    Arch Dermatol Res; 1991; 283(7):480-2. PubMed ID: 1724898
    [No Abstract]   [Full Text] [Related]  

  • 94. The effect of anthralin and its derivatives on epidermal cell kinetics.
    Fisher LB; Maibach HI
    J Invest Dermatol; 1975 May; 64(5):338-41. PubMed ID: 1141709
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Study of proliferative activity and nucleolar organizers in the epidermis of patients with psoriasis].
    Tereshin KIa; Tsygankov VI; Fleĭshman MIu; Mel'nikova NP
    Klin Lab Diagn; 2002 Jan; (1):39-40. PubMed ID: 11855340
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Calmodulin activity in the psoriatic epidermis.
    Kusakabe Y; Iizuka H; Matsuo S; Kajita S; Tsutsui M; Mizumoto T; Ohkawara A; Yamauchi T
    J Dermatol; 1984 Apr; 11(2):111-6. PubMed ID: 6384305
    [No Abstract]   [Full Text] [Related]  

  • 97. Mitotic index of psoriatic lesions treated with anthralin, glucocorticosteriod and occlusion only.
    Baxter DL; Stoughton RB
    J Invest Dermatol; 1970 May; 54(5):410-2. PubMed ID: 5440026
    [No Abstract]   [Full Text] [Related]  

  • 98. Immunohistochemical demonstration of cytokeratin 19-positive basal cells in psoriatic plaques.
    Wollina U; Karsten U
    Arch Dermatol Res; 1988; 280(4):257-8. PubMed ID: 2466444
    [No Abstract]   [Full Text] [Related]  

  • 99. Epidermal cell kinetics in psoriasis.
    Grove GL
    Int J Dermatol; 1979 Mar; 18(2):111-22. PubMed ID: 370039
    [No Abstract]   [Full Text] [Related]  

  • 100. Physico-chemical properties and stability of anthralin in interaction with albumin, in suction blister fluid and intact human epidermis.
    de sa e Melo MT; Santus R; Dubertret L
    Br J Dermatol; 1981 Aug; 105 Suppl 20():20-2. PubMed ID: 7284259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.